SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 3 - Initial statement of beneficial ownership of securities:
SEC Accession No. 0001209191-22-016848
Filing Date
2022-03-07
Accepted
2022-03-07 19:15:06
Documents
2
Period of Report
2022-02-23

Document Format Files

Seq Description Document Type Size
1 FORM 3 SUBMISSION doc3.html 3  
1 FORM 3 SUBMISSION doc3.xml 3 5000
2 EX-24.1 DOCUMENT attachment1.htm EX-24.1 3969
  Complete submission text file 0001209191-22-016848.txt   10373
Mailing Address 40 ERIE STREET SUITE 130 CAMBRIDGE MA 02139
Business Address 40 ERIE STREET SUITE 130 CAMBRIDGE MA 02139 857-285-6200
Intellia Therapeutics, Inc. (Issuer) CIK: 0001652130 (see all company filings)

IRS No.: 364785571 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2835 In Vitro & In Vivo Diagnostic Substances

Mailing Address C/O INTELLIA THERAPEUTICS, INC. 40 ERIE STREET, SUITE 130 CAMBRIDGE MA 02139
Business Address
Clark Eliana (Reporting) CIK: 0001914448 (see all company filings)

Type: 3 | Act: 34 | File No.: 001-37766 | Film No.: 22719867